View Ontology Report


Gefitinib belongs to a class of tyrosine kinase inhibitors (TKI) designed to compete with ATP for binding into the ATP binding pocket of mutated or over-expressed receptor and thus inhibit its tyrosine kinase activity and the signaling events downstream of it. Gefitinib along with erlotinib have been used to target epidermal growth factor receptor, Egfr. Gefitinib, presented here, was among the first and the most widely used TKI for use in the treatment of locally advanced or metastatic non-smal

Pathway Diagram:

Ariadne Genomics Inc. gefitinib side effetcs gefitinib gefitinib pharmacodynamics pathway --+> Rash gefitinib pharmacodynamics pathway --+> GI disturbances gefitinib pharmacodynamics pathway --+> Interstitial Lung Disease gefitinib pharmacodynamics pathway gefitinib pharmacokinetics pathway epidermal growth factor/neuregulin signaling pathway non-small cell lung cancer pathway Carcinoma, Non-Small-Cell Lung GI disturbances Rash Interstitial Lung Disease epidermal growth factor/neuregulin signaling pathway ---| Carcinoma, Non-Small-Cell Lung epidermal growth factor/neuregulin signaling pathway ---| non-small cell lung cancer pathway gefitinib pharmacodynamics pathway ---| epidermal growth factor/neuregulin signaling pathway gefitinib ---> gefitinib pharmacodynamics pathway gefitinib ---> gefitinib pharmacokinetics pathway

Genes in Pathway:

show annotations for term's descendants       view all columns           Sort by:
gefitinib pharmacodynamics pathway term browser
Symbol Object Name JBrowse Chr Start Stop Reference
G Egfr epidermal growth factor receptor JBrowse link 14 99,919,485 100,104,136 RGD:5135288

Additional Elements in Pathway:

(includes Gene Groups, Small Molecules, Other Pathways..etc.)
Object TypePathway ObjectPathway Object Description
DiseaseCarcinoma, Non-Small-Cell lungentry point to the respiratory disease portal
Pathwayepidermal growth factor/neuregulin signaling pathwayEpidermal growth factor/neuregulin signaling pathway plays a central role in the regulation of cell growth, differentiation, proliferation and survival
Small MoleculegefitinibIressa; ZD1839 (AstraZeneca Inc.)
Pathwaynon-small cell lung cancer pathwayLung cancer, a major cause of cancer mortality, has been assigned to two types: small-cell (SCLC) and non-small cell lung cancer (NSCLC). The first, an extremely aggressive form of cancer accounts for ~20% of cases while the second accounts for the remaining ~80%.
Pathwaygefitinib pharmacodynamics pathwayThe pathway of gefitinib-target interaction and of the biochemical or physiological responses to them.
Pathwaygefitinib pharmacokinetics pathwayThe pathway of processing - absorption, distribution, metabolism or elimination - of gefitinib.

Pathway Gene Annotations

References Associated with the gefitinib drug pathway:

Ontology Path Diagram:

paths to the root

Import into Pathway Studio: